Freenome
Freenome Nets $290M Investment From Roche
The company said the latest influx brings its total funding to more than $1 billion and will help the firm expand its cancer detection platform to multiple tumor types.
Freenome Raises $300M in Series D Financing
The company will use the funding to support commercialization of its blood-based colorectal cancer detection test and to fuel expansion to other tumor types.
Freenome, Siemens Healthineers Partner to ID Blood-Based Breast Cancer Biomarkers
The companies aim to use multiomic and other types of data to identify blood-based biomarkers that can help in the early diagnosis of breast cancer.
Freenome Maintains CRC Early Detection Timeline as New Biomarker Discovery Studies Progress
The company is using newly raised funds to support a disseminated trial model, which it said will help it keep its plans to finish the study by the end of 2021.
Freenome Closes $270M Series C Financing to Support Early Cancer Detection Trial
The company said proceeds will accelerate the ongoing FDA registrational study of its blood-based colorectal cancer screening test and further its extended pipeline.